{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-136730","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.242197+00:00","generated_at":"2026-06-02T02:36:49.264774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Benitec reports Q3 net loss $4.3M, positive OPMD data, $40M PIPE closed","bullets":["Net loss of $4.3M ($1.64 EPS) vs $4.4M ($2.67 EPS) in Q3 2023; revenue $0.","Cash $14.1M at Mar 31; subsequent $40M oversubscribed PIPE closed Apr 22 extends runway through 2025.","First OPMD subject showed clinically meaningful improvements in swallowing at 90 days post BB-301 dose; no SAEs.","Second subject dosed safely; third expected June 2024; 23 subjects enrolled in natural history study.","Additional interim safety/efficacy data expected H2 2024; Suvretta Capital led PIPE."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-136730","json":"https://secwatch.observer/filing/0001193125-24-136730.json","markdown":"https://secwatch.observer/filing/0001193125-24-136730.md","text":"https://secwatch.observer/filing/0001193125-24-136730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524136730/0001193125-24-136730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524136730/d792227d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:36:49.264774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c54d356b89cb6fb0f23e61fc0abbf1a582b41c05","claim":"Benitec Biopharma Inc. reported third fiscal quarter ended March 31, 2024 results: revenue $0.","evidence_excerpt":"Total Revenues for the quarter ended March 31, 2024, were $0 compared to $54,000 in licensing revenues collected for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524136730/0001193125-24-136730-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third fiscal quarter ended March 31, 2024"},{"label":"Revenue","value":"$0"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}